Pires Bruno, Rosendo Luana M, Brinca Ana Teresa, Simão Ana Y, Barroso Mário, Rosado Tiago, Gallardo Eugenia
Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior (CICS-UBI), 6201-506 Covilhã, Portugal.
Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, 6200-000 Covilhã, Portugal.
Life (Basel). 2023 Nov 8;13(11):2180. doi: 10.3390/life13112180.
This review delves into the therapeutic applications of amphetamine-type stimulants such as lisdexamphetamine dimesylate, mixed amphetamine salts, 3,4-methylenedioxymethamphetamine (MDMA), dextroamphetamine, and phentermine. These compounds have been investigated for their potential in treating a range of psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), drug dependence, post-traumatic stress disorder (PTSD), and obesity. Lisdexamphetamine dimesylate has shown promise in effectively treating ADHD symptoms in both children and adults. Additionally, it has been explored as a potential treatment for drug dependency and withdrawal, demonstrating encouraging results. Mixed amphetamine salts have also exhibited efficacy in reducing ADHD symptoms in adults. Future research should explore their potential use in treating bipolar disorder and cocaine dependence, considering the associated risks and benefits. MDMA-assisted psychotherapy has emerged as an innovative approach to treating PTSD, leading to sustained reductions in symptoms and even promoting post-traumatic growth. Furthermore, it has shown promise in managing anxiety related to life-threatening illnesses. Dextroamphetamine and phentermine have demonstrated efficacy in treating cocaine and opioid dependence, ADHD, and obesity. However, careful consideration and monitoring by medical professionals are essential due to the potential risks and benefits associated with them. In conclusion, amphetamine-type stimulants present a promising avenue for therapeutic interventions in various psychiatric conditions. Nevertheless, further research is necessary to comprehensively understand their mechanisms of action, dosage requirements, and long-term effects in different patient populations.
本综述深入探讨了苯丙胺类兴奋剂的治疗应用,如赖氨酸右苯丙胺二甲磺酸盐、混合苯丙胺盐、3,4-亚甲基二氧基甲基苯丙胺(摇头丸)、右旋苯丙胺和芬特明。这些化合物已被研究其在治疗一系列精神疾病方面的潜力,包括注意力缺陷多动障碍(ADHD)、药物依赖、创伤后应激障碍(PTSD)和肥胖症。赖氨酸右苯丙胺二甲磺酸盐已显示出在有效治疗儿童和成人ADHD症状方面的前景。此外,它还被探索作为药物依赖和戒断的潜在治疗方法,显示出令人鼓舞的结果。混合苯丙胺盐在减轻成人ADHD症状方面也表现出疗效。未来的研究应探讨它们在治疗双相情感障碍和可卡因依赖方面的潜在用途,同时考虑相关的风险和益处。摇头丸辅助心理治疗已成为治疗PTSD的一种创新方法,可导致症状持续减轻,甚至促进创伤后成长。此外,它在管理与危及生命疾病相关的焦虑方面也显示出前景。右旋苯丙胺和芬特明在治疗可卡因和阿片类药物依赖、ADHD和肥胖症方面已显示出疗效。然而,由于与之相关的潜在风险和益处,医疗专业人员的仔细考虑和监测至关重要。总之,苯丙胺类兴奋剂为各种精神疾病的治疗干预提供了一条有前景的途径。然而,有必要进行进一步研究,以全面了解它们在不同患者群体中的作用机制、剂量要求和长期影响。